In a year-round effort to combat lung cancer, the Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) have announced $400,000 in funding for two promising early-career researchers. The grants, each worth $200,000, support projects that target two of the most critical challenges in lung cancer: early detection and overcoming treatment resistance. This investment comes at a time when lung cancer remains the leading cause of cancer death worldwide, claiming a life in the United States every 4.2 minutes, according to the organizations.
The funding addresses a significant gap in oncology research: many innovative ideas fail to progress due to lack of resources, not lack of vision. By providing this support, LCFA and IASLC aim to help these researchers turn their ideas into life-saving breakthroughs. The Early Career Researcher (ECR) grant program is designed to give emerging scientists the momentum needed to secure major independent research awards, which can launch their careers and accelerate progress in the field.
Dr. Jared Mayers of Fred Hutch Cancer Center is one of this year's recipients. His research focuses on the role of naturally occurring bacteria in the lungs and how they may influence the development of lung cancer. Because these bacteria are present in tiny amounts, they have been difficult to study. Dr. Mayers is developing highly sensitive techniques to capture and analyze these microbes, aiming to map their contribution to cancer and uncover new ways to prevent the disease. "We don't get new drugs, we don't get new therapies, we don't get longer lives, better quality lives, more time with family unless we invest in the upfront groundwork," he said.
Dr. Jaime L. Schneider of Dana-Farber Cancer Institute is the other recipient. Her project investigates how lung cancer cells adapt and survive after treatment, focusing on their energy management and potential weak points. The goal is to design more effective therapies that prevent cancer from developing resistance to standard chemotherapy and targeted treatments. Dr. Schneider, drawn to thoracic oncology by the "tremendous arsenal of new drugs," aims to offer better and longer-lasting options for patients.
The timing of this funding is urgent, as competition for research dollars intensifies each year. The LCFA's Early Career Research Grant Program has a proven "multiplier effect," with a current return on investment of 13 times. To date, the program has awarded 25 grants totaling $4.6 million, which has grown into more than $50 million in additional funding from other organizations. This track record means that Dr. Mayers and Dr. Schneider are not just receiving funding; they are gaining a foundation to secure major, long-term support for their work.
Kim Norris, co-founder and president of LCFA, emphasized the importance of supporting early-career investigators: "Supporting early-career investigators is not just a strategic priority. It is a necessity for the future of oncology. By investing in these researchers, we are accelerating the pace of discovery and ensuring that promising ideas in metabolic tracking and drug resistance can move from the laboratory to the clinic, where they are needed most."
The $400,000 investment underscores the ongoing commitment of LCFA and IASLC to accelerate discovery for patients everywhere. For more information about lung cancer and resources, visit lcfamerica.org.
